- Open
- 178.00
- High
- 182.13
- Low
- 174.00
- Close
- 177.25
- Change
- -5.50 (-3.05%)
- Volume
- 13,780
⌘K
| 22 May 2026 | 07:00:06 | HUTCHMED Highlights Data to be Presented at ASCO |
| 21 May 2026 | 11:00:01 | NMPA approval for ELUNATE with TYVYT |
| 12 May 2026 | 12:45:00 | Announcement on Results of Annual General Meeting |
| 30 Apr 2026 | 09:30:00 | Total Voting Rights |
| 29 Apr 2026 | 11:00:00 | HUTCHMED Announces NDA Acceptance in China |
HUTCHMED is a biopharmaceutical company that focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases on a global scale. They are dedicated to innovation and commercialization in the field of biopharmaceuticals.
| 22 May 2026 | 07:00:06 | HUTCHMED Highlights Data to be Presented at ASCO |
| 21 May 2026 | 11:00:01 | NMPA approval for ELUNATE with TYVYT |
| 12 May 2026 | 12:45:00 | Announcement on Results of Annual General Meeting |
| 30 Apr 2026 | 09:30:00 | Total Voting Rights |
| 29 Apr 2026 | 11:00:00 | HUTCHMED Announces NDA Acceptance in China |
HUTCHMED is a biopharmaceutical company that focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases on a global scale. They are dedicated to innovation and commercialization in the field of biopharmaceuticals.